Roy M Fleischmann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5568624/publications.pdf

Version: 2024-02-01

183	20,865	24978	9553
papers	citations	57 h-index	142 g-index

183	183	183	10229
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate. New England Journal of Medicine, 1999, 340, 253-259.	13.9	2,044
2	A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis. New England Journal of Medicine, 2000, 343, 1586-1593.	13.9	1,776
3	Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)â€“Fc Fusion Protein. New England Journal of Medicine, 1997, 337, 141-147.	13.9	1,586
4	The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis and Rheumatism, 2006, 54, 1390-1400.	6.7	951
5	Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. New England Journal of Medicine, 2012, 367, 495-507.	13.9	826
6	Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis. New England Journal of Medicine, 2012, 367, 508-519.	13.9	810
7	Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis and Rheumatism, 2003, 48, 3230-3236.	6.7	707
8	Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis and Rheumatism, 2002, 46, 1443-1450.	6.7	664
9	Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. New England Journal of Medicine, 2022, 386, 316-326.	13.9	640
10	Tofacitinib versus Methotrexate in Rheumatoid Arthritis. New England Journal of Medicine, 2014, 370, 2377-2386.	13.9	630
11	Tofacitinib (CPâ€690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelveâ€month data from a twentyâ€fourâ€“month phase III randomized radiographic study. Arthritis and Rheumatism, 2013, 65, 559-570.	6.7	481
12	Golimumab, a human antiâ€“tumor necrosis factor Î± monoclonal antibody, injected subcutaneously every four weeks in methotrexateâ€naive patients with active rheumatoid arthritis: Twentyâ€fourâ€“week results of a phase III, multicenter, randomized, doubleâ€blind, placeboâ€controlled study of golimumab before methotrexate as firstâ€line therapy for earlyâ€onset rheumatoid arthritis. Arthritis and Rheumatism, 2009, 60, 2272-2283.	6.7	387
13	Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. Annals of Internal Medicine, 2013, 159, 253.	2.0	381
14	Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu. Arthritis and Rheumatism, 2011, 63, 609-621.	6.7	369
15	Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet, The, 2017, 390, 457-468.	6.3	360
16	Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	11.0	356
17	Phase IIb doseâ€ranging study of the oral JAK inhibitor tofacitinib (CPâ€690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to diseaseâ€modifying antirheumatic drugs. Arthritis and Rheumatism, 2012, 64, 617-629.	6.7	339
18	Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet, The, 2018, 391, 2513-2524.	6.3	316

#	Article	IF	Citations
19	Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Diseaseâ€Modifying Antirheumatic Drug Treatment. Arthritis and Rheumatology, 2017, 69, 506-517.	2.9	310
20	Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase <scp>III</scp>, Doubleâ€Blind, Randomized Controlled Trial. Arthritis and Rheumatology, 2019, 71, 1788-1800.	2.9	284
21	Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials. Journal of Rheumatology, 2010, 37, 558-567.	1.0	265
22	Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Annals of the Rheumatic Diseases, 2014, 73, 86-94.	0.5	256
23	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet, The, 2014, 383, 321-332.	6.3	232
24	Headâ€toâ€head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis and Rheumatism, 2013, 65, 28-38.	6.7	225
25	Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis and Rheumatology, 2015, 67, 1424-1437.	2.9	213
26	Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. Journal of Rheumatology, 2015, 42, 1761-1766.	1.0	194
27	Sarilumab, a fully human monoclonal antibody against IL-6RÎ± in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Annals of the Rheumatic Diseases, 2014, 73, 1626-1634.	0.5	173
28	Pharmacokinetics and Safety of Golimumab, a Fully Human Anti-TNF-Î± Monoclonal Antibody, in Subjects With Rheumatoid Arthritis. Journal of Clinical Pharmacology, 2007, 47, 383-396.	1.0	172
29	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 2021, 80, 71-87.	0.5	158
30	Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib. Arthritis and Rheumatology, 2015, 67, 616-625.	2.9	157
31	Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care and Research, 2012, 64, 1794-1803.	1.5	149
32	Sarilumab and Nonbiologic Diseaseâ€Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis and Rheumatology, 2017, 69, 277-290.	2.9	146
33	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet, The, 2016, 388, 2763-2774.	6.3	144
34	A Phase <scp>II</scp> Trial of Lutikizumab, an Antiâ€“Interleukinâ€1Î±/Î² Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis and Rheumatology, 2019, 71, 1056-1069.	2.9	137
35	Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Annals of the Rheumatic Diseases, 2016, 75, 709-714.	0.5	134
36	Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Annals of the Rheumatic Diseases, 2014, 73, 1607-1615.	0.5	125

#	Article	IF	Citations
37	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology, 2012, 51, 2204-2214.	0.9	115
38	Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Annals of the Rheumatic Diseases, 2019, 78, 1454-1462.	0.5	115
39	Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1Î± and anti-interleukin-1Î² dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Annals of the Rheumatic Diseases, 2019, 78, 413-420.	0.5	115
40	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: TableÂ1. Annals of the Rheumatic Diseases, 2013, 72, ii2-ii34.	0.5	114
41	A Randomized, Doubleâ€Blind, Placeboâ€Controlled, Twelveâ€Week, Doseâ€Ranging Study of Decernotinib, an Oral Selective JAKâ€3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 334-343.	2.9	98
42	How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?. Annals of the Rheumatic Diseases, 2015, 74, 1132-1137.	0.5	95
43	Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology, 2014, 53, 2167-2174.	0.9	92
44	Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. Journal of Rheumatology, 2006, 33, 234-43.	1.0	91
45	Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open, 2018, 4, e000656.	1.8	90
46	Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 1232-42.	1.0	89
47	Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Current Opinion in Rheumatology, 2010, 22, 330-335.	2.0	87
48	Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results. Journal of Rheumatology, 2013, 40, 113-126.	1.0	87
49	Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Annals of the Rheumatic Diseases, 2015, 74, 538-546.	0.5	75
50	DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. RMD Open, 2017, 3, e000382.	1.8	71
51	Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. Journal of Rheumatology, 2003, 30, 691-6.	1.0	66
52	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twentyâ€Fourâ€“Month, Phase <scp>III</scp> Study. Arthritis and Rheumatology, 2019, 71, 878-891.	2.9	64
53	Novel small-molecular therapeutics for rheumatoid arthritis. Current Opinion in Rheumatology, 2012, 24, 335-341.	2.0	62
54	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology, 2016, 55, 1031-1041.	0.9	62

#	Article	IF	Citations
55	Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis. Rheumatology and Therapy, 2018, 5, 283-291.	1.1	62
56	Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab. Seminars in Arthritis and Rheumatism, 2009, 38, 265-280.	1.6	61
57	Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 2016, 75, 1293-1301.	0.5	61
58	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 1290-1297.	0.5	61
59	Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care and Research, 2011, 63, 373-382.	1.5	58
60	Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opinion on Drug Safety, 2004, 3, 391-403.	1.0	56
61	Risk???:???Benefit Profile of Etanercept in??Elderly Patients with Rheumatoid Arthritis, Ankylosing Spondylitis or??Psoriatic Arthritis. Drugs and Aging, 2007, 24, 239-254.	1.3	56
62	Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Research and Therapy, 2015, 17, 307.	1.6	53
63	Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. RMD Open, 2016, 2, e000308.	1.8	50
64	Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. Journal of Clinical Medicine, 2019, 8, 831.	1.0	50
65	Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open, 2022, 8, e002012.	1.8	50
66	Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?. Rheumatology and Therapy, 2020, 7, 35-64.	1.1	49
67	Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Research and Therapy, 2017, 19, 208.	1.6	48
68	Meloxicam. Expert Opinion on Pharmacotherapy, 2002, 3, 1501-1512.	0.9	47
69	Does safety make a difference in selecting the right TNF antagonist?. Arthritis Research, 2004, 6, S12.	2.0	47
70	A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂ®) in the treatment of active rheumatoid arthritis. Arthritis Research and Therapy, 2018, 20, 178.	1.6	44
71	Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 yearsâ€™ follow-up. Rheumatology, 2020, 59, 292-302.	0.9	43
72	A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?. Arthritis and Rheumatology, 2021, 73, 2166-2178.	2.9	43

#	Article	IF	Citations
73	Brief Report: Estimating Disease Activity Using Multiâ€Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab. Arthritis and Rheumatology, 2016, 68, 2083-2089.	2.9	42
74	Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib. Clinical Rheumatology, 2006, 25, 42-53.	1.0	40
75	Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis. RMD Open, 2017, 3, e000546.	1.8	39
76	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open, 2020, 6, e001374.	1.8	36
77	4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open, 2018, 4, e000582.	1.8	34
78	Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors. RMD Open, 2017, 3, e000416.	1.8	33
79	Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open, 2017, 3, e000491.	1.8	33
80	Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. RMD Open, 2018, 4, e000584.	1.8	33
81	A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Seminars in Arthritis and Rheumatism, 2018, 48, 406-415.	1.6	32
82	Ixekizumab treatment of biologic-naÃ¯ve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology, 2020, 59, 2774-2784.	0.9	31
83	Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open, 2019, 5, e001040.	1.8	28
84	Safety, Tolerability, and Pharmacodynamics of <scp>ABT</scp>â€122, a Tumor Necrosis Factorâ€ and Interleukinâ€17â€Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2017, 69, 2283-2291.	2.9	27
85	Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. International Journal of Rheumatic Diseases, 2016, 19, 1216-1225.	0.9	26
86	Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitorâ€methotrexate combination therapy versus triple therapy in rheumatoid arthritis. RMD Open, 2017, 3, e000371.	1.8	26
87	Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study. Clinical Rheumatology, 2018, 37, 2381-2390.	1.0	26
88	Efficacy and Safety of Longâ€Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate. Arthritis Care and Research, 2020, 72, 1112-1121.	1.5	25
89	Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial. Rheumatology and Therapy, 2020, 7, 327-344.	1.1	25
90	Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology, 2022, 61, 2413-2423.	0.9	25

#	Article	IF	Citations
91	Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open, 2016, 2, e000262.	1.8	24
92	Patientâ€Reported Outcomes From a Twoâ€Year Headâ€toâ€Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 907-913.	1.5	24
93	Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study. Arthritis Care and Research, 2020, 72, 353-359.	1.5	23
94	Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. Clinical and Experimental Rheumatology, 2016, 34, 430-42.	0.4	23
95	Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 289-292.	0.5	22
96	Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis Research and Therapy, 2020, 22, 139.	1.6	21
97	Interleukin-6 receptor blockade or TNFÎ± inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Research and Therapy, 2020, 22, 206.	1.6	20
98	Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. Expert Opinion on Drug Safety, 2003, 2, 347-365.	1.0	19
99	A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate. Expert Opinion on Pharmacotherapy, 2017, 18, 1525-1533.	0.9	19
100	Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. Journal of Rheumatology, 2018, 45, 177-187.	1.0	18
101	Developing a New Generation of TNFÂ Antagonists for the Treatment of Rheumatoid Arthritis. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2003, 3, 310-318.	3.4	18
102	Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. Rheumatology, 2021, 60, 5583-5594.	0.9	17
103	Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis. BMC Musculoskeletal Disorders, 2008, 9, 32.	0.8	16
104	Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Research and Therapy, 2015, 17, 325.	1.6	16
105	Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naÃ¯ve patients with rheumatoid arthritis. RMD Open, 2016, 2, e000232.	1.8	16
106	Editorial: The American College of Rheumatology White Paper on Biosimilars: It Isn't All Whiteâ€"There Is Some Gray and Black. Arthritis and Rheumatology, 2018, 70, 323-325.	2.9	16
107	Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). Rheumatology and Therapy, 2019, 6, 559-571.	1.1	15
108	Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. RMD Open, 2022, 8, e001994.	1.8	15

#	Article	IF	Citations
109	Anakinra in the treatment of rheumatic disease. Expert Review of Clinical Immunology, 2006, 2, 331-340.	1.3	14
110	Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2021, 80, 432-439.	0.5	14
111	Don't forget traditional DMARDs. Rheumatology, 2011, 50, 429-430.	0.9	13
112	Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study. Current Medical Research and Opinion, 2014, 30, 2139-2149.	0.9	13
113	Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. Arthritis Research and Therapy, 2015, 17, 343.	1.6	13
114	Tofacitinib in the treatment of active rheumatoid arthritis in adults. Immunotherapy, 2018, 10, 39-56.	1.0	12
115	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: TableÂ1. Annals of the Rheumatic Diseases, 2014, 73, 1755-1760.	0.5	11
116	Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients. Rheumatology and Therapy, 2017, 4, 57-69.	1.1	11
117	Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors. Rheumatology, 2021, 60, 4991-5001.	0.9	11
118	Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study. RMD Open, 2018, 4, e000647.	1.8	11
119	Recent issues in JAK inhibitor safety: perspective for the clinician. Expert Review of Clinical Immunology, 2022, 18, 295-307.	1.3	11
120	Comparison of the Efficacy of Biologic Therapy for Rheumatoid Arthritis: Can the Clinical Trials Be Accurately Compared?. Rheumatic Disease Clinics of North America, 2006, 32, 21-28.	0.8	10
121	Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis. Rheumatology, 2014, 53, 1984-1993.	0.9	10
122	Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis. Rheumatology and Therapy, 2018, 5, 203-214.	1.1	10
123	Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26â€“52, including a treatment switch from reference ADL to PF-06410293. RMD Open, 2021, 7, e001578.	1.8	10
124	Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (HumiraÂ®) or continuing biosimilar therapy: week 52â€“92 data from a randomized, double-blind, phase 3 trial. Arthritis Research and Therapy, 2021, 23, 248.	1.6	9
125	Value of the Multibiomarker Disease Activity Score to Predict Remission in RA: What Does the Evidence Show?. Journal of Rheumatology, 2019, 46, 443-446.	1.0	8
126	Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritis. Expert Opinion on Drug Safety, 2020, 19, 935-944.	1.0	8

#	Article	IF	Citations
127	Methodological aspects and the interpretation of clinical trial data: lessons from the TEAR trial. Rheumatology, 2013, 52, 409-410.	0.9	7
128	Interleukin-6 inhibition for rheumatoid arthritis. Lancet, The, 2017, 389, 1168-1170.	6.3	7
129	Primer: establishing a clinical trial unitâ€"regulations and infrastructure. Nature Clinical Practice Rheumatology, 2007, 3, 234-239.	3.2	6
130	Developing new oral targeted therapies for RA can be challenging. Nature Reviews Rheumatology, 2015, 11, 4-6.	3.5	6
131	Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials. Arthritis Research and Therapy, 2019, 21, 231.	1.6	6
132	Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients. Drugs in Context, 2020, 9, 1-15.	1.0	6
133	Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study. Clinical and Experimental Rheumatology, 2020, 38, 848-857.	0.4	6
134	EULAR PsA management recommendations 2019: can the recommendations be improved?. Annals of the Rheumatic Diseases, 2020, 79, 700.2-712.	0.5	5
135	Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND. Journal of Rheumatology, 2022, 49, 133-141.	1.0	5
136	Treatment of early rheumatoid arthritis. Modern Rheumatology, 2005, 15, 153-162.	0.9	5
137	Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III. Clinical and Experimental Rheumatology, 2016, 34, 32-6.	0.4	5
138	Treatment of early rheumatoid arthritis. Modern Rheumatology, 2005, 15, 153-162.	0.9	4
139	Primer: establishing a clinical trial unitâ€"obtaining studies and patients. Nature Clinical Practice Rheumatology, 2007, 3, 459-463.	3.2	4
140	2019 update of the American College of Rheumatologyâ€“ recommended rheumatoid arthritis disease activity measures: comment on the article by England et al. Arthritis Care and Research, 2020, 72, 736-736.	1.5	4
141	Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib. RMD Open, 2021, 7, e001609.	1.8	4
142	Benefitâ€"Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. Rheumatology and Therapy, 2022, 9, 191-206.	1.1	4
143	Examining the efficacy of biologic therapy: are there real differences?. Journal of rheumatology Supplement, The, 2002, 65, 27-32.	2.2	4
144	Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis. Rheumatology and Therapy, 2022, 9, 839-850.	1.1	4

#	Article	IF	Citations
145	Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid Arthritis. Rheumatology and Therapy, 2022, 9, 435-446.	1.1	4
146	Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial. Lancet Rheumatology, The, 2022, 4, e395-e406.	2.2	4
147	Etanercept â€“ review of efficacy and safety after five years of clinical use. Therapy: Open Access in Clinical Medicine, 2004, 1, 11-23.	0.2	3
148	The efficacy and safety of golimumab in the treatment of arthritis. Expert Opinion on Biological Therapy, 2010, 10, 1131-1143.	1.4	3
149	Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration. RMD Open, 2016, 2, e000210.	1.8	3
150	Reply. Arthritis and Rheumatology, 2017, 69, 867-868.	2.9	3
151	THU0193â€…EFFICACY OF TOFACITINIB MONOTHERAPY, TOFACITINIB WITH METHOTREXATE AND ADALIMUMAB WITH METHOTREXATE IN PATIENTS WITH EARLY (â‰2 YEARS) VS ESTABLISHED (>2 YEARS) RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STRATEGY. , 2019, , .		3
152	Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation? Comment on article by Boeters DM et al.. Arthritis Research and Therapy, 2020, 22, 17.	1.6	3
153	Safety and efficacy of etanercept in the elderly. Aging Health, 2006, 2, 189-197.	0.3	3
154	Is there a need for new therapies for rheumatoid arthritis?. Journal of rheumatology Supplement, The, 2005, 73, 3-7; discussion 29-30.	2.2	3
155	Oral Abstracts 7: RA Clinical * O37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach. Rheumatology, 2013, 52, i44-i55.	0.9	2
156	Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy. Arthritis Research and Therapy, 2021, 23, 220.	1.6	2
157	Response to: â€˜Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registryâ€™ by Favalli et al. Annals of the Rheumatic Diseases, 2015, 74, e6-e6.	0.5	1
158	Living with Psoriatic Arthritis: A Patientâ€™s and Physicianâ€™s Perspective. Rheumatology and Therapy, 2016, 3, 1-4.	1.1	1
159	223â€ƒSustained response in a phase III study of sarilumab plus nonbiologic disease modifying anti-rheumatic drugs in patients with active, moderate-to-severe rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Rheumatology, 2018, 57, .	0.9	1
160	074â€ƒSummary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis. Rheumatology, 2019, 58, .	0.9	1
161	081â€ƒLong-term safety with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs and sarilumab monotherapy in rheumatoid arthritis: an integrated analysis with 9,000 patient-years of follow-up. Rheumatology, 2019, 58, .	0.9	1
162	054â€ƒEffect of sarilumab on glycosylated hemoglobin in patients with rheumatoid arthritis and diabetes. Rheumatology, 2019, 58, .	0.9	1

#	Article	IF	Citations
163	THU0075â€…EARLY VERSUS DELAYED START OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A PHASE 3 TRIAL OF PATIENTS NAÃVE TO METHOTREXATE TREATMENT. , 2019, , .		1
164	Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis. Arthritis Care and Research, 2022, 74, 1477-1483.	1.5	1
165	Etanercept - review of efficacy and safety after five years of clinical use. Therapy: Open Access in Clinical Medicine, 2004, 1, 11-23.	0.2	1
166	Clinical studies can be performed in an ethical manner. Nature Clinical Practice Rheumatology, 2008, 4, E5-E5.	3.2	1
167	Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis. Rheumatology and Therapy, 2022, 9, 649-661.	1.1	1
168	Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?. Annals of the Rheumatic Diseases, 2014, 73, e54-e54.	0.5	0
169	86.â€ƒHead-to-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in Rheumatoid Arthritis: Blinded Two-Year Results from the Ample Study. Rheumatology, 2014, 53, i88-i88.	0.9	0
170	Reply to letter to the editor with regards to manuscript AR-15-1750.R1. Arthritis and Rheumatology, 2016, , .	2.9	0
171	217â€ƒImprovementsin remission and low disease activity are achieved with ongoing sarilumabtreatment, in patients with rheumatoid arthritis in two phase III studies. Rheumatology, 2018, 57, .	0.9	0
172	076â€ƒAssessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors. Rheumatology, 2019, 58, .	0.9	0
173	THU0170â€…A MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF REPOSITORY CORTICOTROPIN INJECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: INTERIM DATA FROM THE OPEN-LABEL TREATMENT PERIOD. , 2019, , .		0
174	Dr. Fleischmann replies. Journal of Rheumatology, 2019, 46, 1642.2-1642.	1.0	0
175	A Summary of 2018 and What Lies Ahead for Rheumatology and Therapy in 2019. Rheumatology and Therapy, 2019, 6, 1-3.	1.1	0
176	Looking Back on 2019 in Rheumatology and What to Expect from 2020. Rheumatology and Therapy, 2020, 7, 1-3.	1.1	0
177	Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis. Journal of Clinical Medicine, 2020, 9, 2017.	1.0	0
178	Tofacitinib monotherapy in psoriatic arthritisâ€”what is missing?. Lancet Rheumatology, The, 2021, 3, e3-e5.	2.2	0
179	P134â€ƒRadiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with RA: results from RA-BEYOND. Rheumatology, 2021, 60, .	0.9	0
180	The Results of Well-conducted Negative Clinical Trials Should Be Reported in a Peer-reviewed Journal. Journal of Rheumatology, 2021, 48, jrheum.201622.	1.0	0

#	Article	IF	Citations
181	Current Treatment Strategies in Rheumatoid Arthritis After Methotrexate Are Not Enough to Maintain Sustained Remission: There Is No Holy Grail!. Arthritis and Rheumatology, 2021, 73, 1124-1126.	2.9	0
182	Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis. Clinical Rheumatology, 2021, 40, 4369-4372.	1.0	0
183	OA27â€ƒSustainability of response between upadacitinib and adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE trial. Rheumatology, 2022, 61, .	0.9	0